GAMUNEX (normal human immunoglobulin) - Measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (0-18 years)
Reason for request
Inscription : Extension d'indication.
L'essentiel
Avis favorable au remboursement dans la prophylaxie pré-/post-exposition contre la rougeole pour les adultes, enfants et adolescents (0-18 ans) à risque chez qui la vaccination active est contre-indiquée ou déconseillée.
Quel progrès ?
Pas de progrès dans la stratégie thérapeutique.
Clinical Benefit
Substantial |
The clinical benefit of GAMUNEX (normal human immunoglobulin) is high in measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (0-18 years) in whom active immunisation is contraindicated or not advised. |
Clinical Added Value
no clinical added value |
GAMUNEX (normal human immunoglobulin) provides no clinical added value (CAV V) in measles pre-/post exposure prophylaxis for susceptible adults, children and adolescents (0-18 years) in whom active immunisation is contraindicated or not advised. |